Nkarta Inc., a biotechnology company based in South San Francisco, United States, continues its operations within the healthcare sector, focusing on the discovery and development of therapies for cancer indications and immune system disorders. The company serves patients located in the state of California.

As of the market close on November 16, 2026, Nkarta Inc. was trading at a price of 1.25 USD on the Nasdaq stock exchange. The company’s market capitalization is valued at 86,760,000 USD. Financial metrics indicate a price-to-earnings ratio of -0.7.

Regarding the company’s stock performance over the past year, the 52-week high was recorded at 3.72 USD on July 8, 2026, while the 52-week low was reached at 1.105 USD on November 12, 2026. Further details regarding the company’s therapeutic developments and activities are available through its official website at www.nkartatx.com .